Description: Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are found in the bodily fluids of humans and food. The Company is reviewing data of its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. All Phase II clinical trials are for the treatment of a range of cancers using only a combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons, however, a few trials use oral formulations. The Company is also conducting laboratory research involving new generations of Antineoplastons, A10 and AS2-1.
Home Page: www.burzynskiclinic.com
9432 Katy Freeway
Houston,
TX
77055
United States
Phone:
713 335 5697
Officers
| Name | Title |
|---|---|
| Dr. Stanislaw R. Burzynski | Chairman, CEO & Pres |
| Mr. Patryk P. Goscianski | Treasurer & Sec. |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2190.8074 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | February |
| Full Time Employees: | 0 |